Skip to main contentrtttttt Skip to main content
Integrative Psychiatry

Advanced Nutraceuticals by Lawrence Cormier, MD

By February 16, 2021March 6th, 2024No Comments

There’s nothing inferior about being an integrative mental health practitioner who focuses on identifying symptom clusters and patterns, and then proceeding with a nutraceutical treatment plan thereafter.

While identifying root causes is more at the root of functional medicine and integrative psychiatry, they both lead to treatment and to happy patients.

Learn more about Advanced Nutraceuticals with Dr. Lawrence Cormier by watching this video.

FULL TRANSCRIPT

There’s nothing inferior about being an integrative mental health practitioner who focuses on identifying symptom clusters and patterns, and then proceeding with a nutraceutical treatment plan thereafter.

While identifying root causes is more at the root of functional medicine and integrative psychiatry, they both lead to treatment and to happy patients.

Often, your initial nutraceutical interventions can get you on first base and can produce some benefits during the first month of a treatment while you’re pursuing the more time-consuming, expensive diagnostic tests in the functional medicine realm while you’re doing gut work, dietary and other interventions that take more time to take root.

Nutraceuticals Overview – Safety

Since matters of safety, informed consent…efficacy is really fundamental to integrative practice, to feeling comfortable treating patients with nutraceuticals. Individuals who are ill, they might have suicidal ideation. How comfortable are you treating someone you know, with someone who is depressed with suicidal ideation, for instance, someone who is in an active bipolar state? Some general considerations regarding safety as quality control.

Even some of the high-end products that are manufactured in the US are using base products that are manufactured in China and India, as are most pharmaceuticals nowadays as well, different formulations even for the same biotherapy, particularly if we’re talking about botanicals. There could be interactions, even though there are nutraceuticals, these are real therapies. And then there’s ethical considerations including selling products in your office. And then you don’t want to promote too much the mentality that the only way to help someone is a pill, you know, and then for the patient, there will often be greater out of pocket costs, the pill burden, multiple dosages per day. And then you know, they buy different products they think are the same.

It’s really important to be a bit compulsive about monitoring the products the patient is taking at your follow up appointments. Don’t fall into a complacent state. The patient will come in and they’re in a different state of symptom relapse or new side effects. They say they’re taking the same product; it was on sale at the end cap at the supermarket and you find out it’s actually something different.

Magnesium

Magnesium is an essential nutrient, a giant in terms of micronutrients, often overlooked, it doesn’t, you know, hold the same potency perhaps that SAM-e and many other bio therapies do. They can be interactions, very well tolerated. In terms of serious safety concerns, although GI side effects are common, if someone has chronic kidney disease, you need to be mindful of that since you can get a greater retention.

More Nutraceuticals – Essential Nutrient for Depression

B vitamins can be used as monotherapies, but most of the evidence bases as adjuncts. We have B6, B9 and B12 that really stand out for the CNS. But really, it’s you know, there’s value in all of the B vitamins. The use of methyl folate is to some degree in my mind determined by a person’s MTHFR status, it’s a test that you can get down with Quest and LabCorp. Most insurance plans will cover it. Medicare does not so you don’t get your patient stuck with a $400 list price bill. Vitamin C. I don’t really think of it. But I mean this is actually a substantial evidence base, mostly from last century.

Sara Reed, MS, LMFT

Sara Reed is a Licensed Marriage and Family Therapist and CEO of Mind’s iHealth Solutions, a digital health company that provides evidence based and culturally responsible mental health services for underserved groups. As a mental health futurist and clinical researcher, Sara examines the ways culture informs the way we diagnose and treat mental illness. Sara’s prior research work includes participation as a study therapist in psychedelic therapy research at Yale University and the University of Connecticut’s Health Center. Sara was the first Black therapist to provide MDMA-assisted psychotherapy in a clinical trial and continues to engage in ongoing advocacy work around health equity in psychedelic medicine.

https://psychiatryinstitute.com/wp-content/uploads/2019/11/Jeffrey-Guss.png

Jeffrey Guss, MD is a psychiatrist, psychoanalyst, and researcher with specializations in psychoanalytic therapy and the treatment of substance use disorders. He was Co-Principal Investigator and Director of Psychedelic Therapy Training for the NYU School of Medicine’s study on psychedelic-assisted psychotherapy in the treatment of cancer-related existential distress, which was published in Journal of Psychopharmacology, 2016. He currently is a study therapist in the NYU study on Psychedelic-Assisted therapy in the treatment of Alcoholism, a collaborator with Yale University’s study on psychedelic-assisted therapy for Major Depressive Disorder and a study therapist with the MAPS (Multidisciplinary Association for Psychedelic Studies) study on treatment of Post Traumatic Stress Disorder with Psychedelic-Assisted Psychotherapy. 

Dr. Guss is interested in the integration of psychedelic therapies with contemporary psychoanalytic theory and has published in Studies in Gender and Sexuality and Psychoanalysis, Culture and Society. He has published (with Elizabeth Nielson, PhD) a paper on “the influence of therapists’ first had experience with psychedelics on psychedelic-assisted psychotherapy research and therapist training” in The Journal of Psychedelic Studies, August, 2018. He is an Instructor and Mentor with the California Institute of Integral Studies’ Center for Psychedelic Therapies and Supervisor in NYU’s Fellowship in Addiction Psychiatry. 

Dr. Guss maintains a private practice in New York City.

Will Van Derveer, MD

Will Van Derveer, MD is Co-Founder of Integrative Psychiatry Institute and Integrative Psychiatry Centers. Dr. Van Derveer was co-investigator on a phase 2 MAPS study of Psychedelic-assisted psychotherapy for treatment-resistant PTSD, and co-authored the publication of this study in 2018. He has also provided Psychedelic-assisted psychotherapy in two MAPS training studies. An active provider of KAP at his clinic in Boulder, CO, he has been teaching others KAP therapy for several years. Dr. Van Derveer contributed a chapter on mescaline in the 2021 "Handbook of Medical Hallucinogens" (edited by Charles Grob and Jim Grigsby). He is co-host of the Higher Practice Podcast.

Dr. Van Derveer regards unresolved emotional trauma as the most significant under-recognized root cause of psychiatric symptoms in integrative psychiatry practice, along with gut issues, hormone imbalances, inflammation, mitochondrial dysfunction, and other functional medicine challenges. He is trained in Somatic Experiencing, EMDR, Internal Family Systems, and other psychotherapy techniques. His current clinical passion is psychedelic-assisted psychotherapy, which he mentors interested doctors in providing. An avid meditator, he has been a meditation instructor since 2004.

For the past several years Dr. Van Derveer has taught psychiatrists and other psychiatric providers integrative psychiatry in a number of settings, including course directing the CU psychiatry residents’ course as well as with Scott Shannon and Janet Settle at the Psychiatry MasterClass.


Scott has been a student of consciousness since his honors thesis on that topic at the University of Arizona in the 1970s under the tutelage of Dr. Andrew Weil. Following medical school, Scott studied Jungian therapy and acupuncture while working as a primary care physician in a rural area for four years. Psychedelic-assisted psychotherapy became a facet of his practice before this medicine was scheduled in 1985. He then completed a psychiatry residency at Columbia program in New York. Scott studied cross-cultural psychiatry and completed a child/adolescent psychiatry fellowship at the University of New Mexico.

In 2010 he founded Wholeness Center in Fort Collins. This innovative clinic provides cross-disciplinary evaluation and care for all mental health concerns. Scott serves as a site Principal Investigator and therapist for the Phase III trial of psychedelic-assisted psychotherapy for PTSD sponsored by (MAPS). He has also published numerous articles about his research on (CBD) in mental health. Currently, Scott works extensively with psychedelic-assisted-psychotherapy. He lectures all over the world to professional groups interested in a deeper look at mental health issues, safer tools, and a paradigm-shifting perspective about transformative care.

Will Van Derveer, MD is co-founder of Integrative Psychiatry Institute (IPI), along with friend and colleague Keith Kurlander, MA. He co-created IPI as an expression of what he stands for. First, that anyone can heal, and second that we medical providers must embrace our own healing journeys in order to fully command our potency as healers.

Dr. Van Derveer spent the last 20 years innovating and testing a comprehensive approach to addressing psychiatric challenges which transcends the conventional model he learned in medical school at Vanderbilt University and residency at University of Colorado, while deeply engaging his own healing path.

He founded the Integrative Psychiatric Healing Center in in 2001 in Boulder, CO, where he currently practices. Dr. Van Derveer regards unresolved emotional trauma as the most significant root cause of psychiatric symptoms in integrative psychiatry practice, along with gut issues, hormone imbalances, inflammation, mitochondrial dysfunction, and other functional medicine challenges. He is trained in Somatic Experiencing, EMDR, Internal Family Systems, and other psychotherapy techniques. His current clinical passion is psychedelic-assisted psychotherapy, which he mentors interested doctors in providing. An avid meditator, he has been a meditation instructor since 2004.

For the past several years Dr. Van Derveer has taught psychiatrists and other psychiatric providers integrative psychiatry in a number of settings, including course directing the CU psychiatry residents’ course as well as with Scott Shannon and Janet Settle at the Psychiatry MasterClass. In addition to his clinical work and teaching, he was co-investigator in 2016 a Phase II randomized clinical trial, sponsored by the Multidisciplinary Association for Psychedelic Studies (MAPS). He continues to support this protocol, now in a Phase III clinical trial under break-through designation by FDA.

Dr. Van Derveer is a diplomate of the American Board of Integrative and Holistic Medicine (ABoIHM) since 2013, and he was board certified in the first wave of diplomates of the new American Board of Integrative Medicine (ABIM) in 2016.